1. Home
  2. GKOS vs DSGX Comparison

GKOS vs DSGX Comparison

Compare GKOS & DSGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$100.96

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Descartes Systems Group Inc. (The)

DSGX

Descartes Systems Group Inc. (The)

HOLD

Current Price

$72.64

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
DSGX
Founded
1998
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.2B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
GKOS
DSGX
Price
$100.96
$72.64
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$133.07
$107.13
AVG Volume (30 Days)
577.7K
657.2K
Earning Date
04-29-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.34
$11.37
Revenue Next Year
$27.46
N/A
P/E Ratio
N/A
$37.05
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$62.56
52 Week High
$130.23
$117.35

Technical Indicators

Market Signals
Indicator
GKOS
DSGX
Relative Strength Index (RSI) 37.84 55.02
Support Level $94.92 $62.63
Resistance Level $104.66 $74.73
Average True Range (ATR) 4.02 2.48
MACD -0.71 0.69
Stochastic Oscillator 22.45 76.65

Price Performance

Historical Comparison
GKOS
DSGX

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About DSGX Descartes Systems Group Inc. (The)

Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.

Share on Social Networks: